UBS Group
PMD

UBS Group’s Psychemedics Corporation PMD Stock Holding History

UBS Group’s Portfolio PMD Stock Details PMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,531
Closed -$4.49K – 10289
2024
Q1 		$4.49K Buy
+1,531
New +$4.85K ﹤0.01% 7622
2023
Q3 		– Sell
-47
Closed -$214 – 10113
2023
Q2 		$214 Sell
47
-76
-62% -$385 ﹤0.01% 8383
2023
Q1 		$646 Sell
123
-4,551
-97% -$25.2K ﹤0.01% 8943
2022
Q4 		$22.9K Buy
4,674
+1,570
+51% +$9.26K ﹤0.01% 7505
2022
Q3 		$20K Buy
3,104
+2,594
+509% +$16.7K ﹤0.01% 7424
2022
Q2 		$3K Sell
510
-1,236
-71% -$7.92K ﹤0.01% 9392
2022
Q1 		$12K Buy
1,746
+511
+41% +$3.62K ﹤0.01% 8211
2021
Q4 		$8K Buy
1,235
+81
+7% +$648 ﹤0.01% 9072
2021
Q3 		$9K Sell
1,154
-1,625
-58% -$11.9K ﹤0.01% 8127
2021
Q2 		$19K Buy
2,779
+2,340
+533% +$16.4K ﹤0.01% 7413
2021
Q1 		$2K Sell
439
-1,088
-71% -$7.21K ﹤0.01% 8661
2020
Q4 		$8K Buy
1,527
+1,482
+3,293% +$6.43K ﹤0.01% 7641
2020
Q3 		$0 Sell
45
-1,335
-97% -$6.5K ﹤0.01% 8500
2020
Q2 		$7K Buy
1,380
+906
+191% +$5.06K ﹤0.01% 7239
2020
Q1 		$3K Sell
474
-2,059
-81% -$17.3K ﹤0.01% 7533
2019
Q4 		$23K Buy
2,533
+623
+33% +$5.75K ﹤0.01% 6798
2019
Q3 		$17K Sell
1,910
-1,525
-44% -$13K ﹤0.01% 6840
2019
Q2 		$35K Buy
+3,435
New +$39K ﹤0.01% 6220
2018
Q4 		– Sell
-5,499
Closed -$103K – 8372
2018
Q3 		$103K Buy
5,499
+5,292
+2,557% +$105K ﹤0.01% 5578
2018
Q2 		$4K Sell
207
-754
-78% -$15.3K ﹤0.01% 7575
2018
Q1 		$21K Buy
+961
New +$20K ﹤0.01% 6390
2017
Q3 		– Sell
-100
Closed -$3K – 8062
2017
Q2 		$3K Sell
100
-1,979
-95% -$41.6K ﹤0.01% 7311
2017
Q1 		$42K Buy
2,079
+596
+40% +$13.1K ﹤0.01% 5654
2016
Q4 		$36K Buy
1,483
+277
+23% +$6.21K ﹤0.01% 6095
2016
Q3 		$24K Buy
1,206
+1,006
+503% +$18.7K ﹤0.01% 6163
2016
Q2 		$3K Hold
200
– – ﹤0.01% 7346
2016
Q1 		$3K Sell
200
-2,408
-92% -$27.6K ﹤0.01% 7216
2015
Q4 		$26K Buy
2,608
+731
+39% +$7.96K ﹤0.01% 6475
2015
Q3 		$19K Buy
1,877
+1,677
+839% +$19.5K ﹤0.01% 6756
2015
Q2 		$3K Sell
200
-1,181
-86% -$18.4K ﹤0.01% 8093
2015
Q1 		$23K Sell
1,381
-1,669
-55% -$26K ﹤0.01% 6864
2014
Q4 		$46K Buy
+3,050
New +$44.3K ﹤0.01% 6593

Other funds holding PMD

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SMP
Santa Monica Partners Palm Beach Gardens, Florida $179M AUM 19.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group's PMD Position: Q2 2024 in Review

UBS Group sold out of Psychemedics Corporation (PMD) in Q2 2024, closing a stake of 1,531 shares — an estimated $4.49K sold.

UBS Group first reported a position in PMD in Q4 2014 and held it in 32 quarters. The position peaked at $103K in Q3 2018. 26 funds tracked by Wall St. Rank hold PMD as of Q2 2024.

  • UBS Group reported no remaining Psychemedics Corporation position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 1,531 Psychemedics Corporation shares in Q2 2024, an estimated $4.49K.
  • UBS Group first reported a position in Psychemedics Corporation in Q4 2014 and held it in 32 quarters.
  • UBS Group's Psychemedics Corporation position peaked at $103K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Psychemedics Corporation as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.